Basic Information
Kovaltry
Regulatory Information
EMEA/H/C/003825
Authorised
February 18, 2016
December 17, 2015
13
December 4, 2024
Company Information
Germany
Kaiser-Wilhelm-Allee 1 51373 Leverkusen
BAYER AG
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Kovaltry. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kovaltry. For practical information about using Kovaltry, patients should read the package leaflet or contact their doctor or pharmacist.